Abstract:
A method for sample encapsulation. A first sampling swab is provided that includes an absorbent portion and a fluid control portion that extends from the absorbent portion. The absorbent portion is proximate a proximal end of the first sampling swab. The fluid control portion is proximate a distal end of the first sampling swab. A sample is collected with the absorbent portion. At least a portion of the sample is liquid. An encapsulation material is provided that includes a first web and a second web. The first sampling swab is positioned between the first web and the second web. The first web is urged into contact with the second web proximate the absorbent portion. The urging of the first web into contact with the second web proximate the absorbent portion causes liquid to move from the absorbent portion towards the fluid control portion. The urging of the first web into contact with the second web proximate the absorbent portion is discontinued which causes the liquid to be drawn into the absorbent portion. The first web is urged into contact with the second web proximate the distal end of the first sampling swab to encapsulate the liquid in the encapsulation material.
Abstract:
An intravaginal urinary incontinence device has an insertion end and an opposed withdrawal end. The device has a resilient frame including a working portion disposed proximate the withdrawal end and an anchoring portion disposed proximate the insertion end. The working portion has a resilient structure having a plurality of connected elongate elements for providing support to an associated urinary system. The anchoring portion has a plurality of connected elongate elements arranged to expand laterally within a user's vagina. The elongate elements are formed of a high modulus polymer having an elastic modulus of at least 2 or 3 GPa. Additionally, the polymer may have an Initial Stress @ 3% Strain of at least about 30 MPa, an elongation at yield of at least 3%, a Stress Ratio of at least about 0.5, and/or an Aged Stress (t=50 hrs @ 40° C) @ 3% Strain is greater than about 35 MPa.
Abstract:
The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein.
Abstract:
A configurable wall module having selectable home screens, custom menu navigation, and incorporating functional design. The display utilizes fixed segments. menu navigation and configuration which may be facilitated with soft keys having indicative labels associated with them. The parameters may be accessed from categories by soft keys via two-level menu navigation. Certain parameter value and setpoint entries may be effected with up/down keys. Module configuration may be performed by a user. To provide such user capability, the module may be programmed and configured by an installer with a software configuration tool used in connection with the building automation system associated with the module.
Abstract:
The present invention provides novel fluoroalkyl tetrabenazine carbinol compounds. The fluoroalkyl tetrabenazine carbinol compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The fluoroalkyl tetrabenazine carbinol compounds are shown to possess high affinity for VMAT-2, a biomarker implicated in human diabetes. The fluoroalkyl tetrabenazine carbinol compounds comprising a fluorine-18 group are useful as PET imaging agents targeting the VMAT-2 biomarker. The non-radiolabled fluoroalkyl tetrabenazine carbinol compounds are useful as probes for the discovery of PET imaging agents.
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB 1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Abstract:
A method of preparing a tetrabenazine compound (TBZ compound) having structure I comprising the steps of reacting a nucleophilic alkenyl species with aldehyde compound II and oxidizing the resultant allylic alcohol to provide enone III. The protecting group P 1 on the tetrahydroisoquinoline nitrogen is removed and the resultant deprotected intermediate is induced to undergo an amino cyclization reaction to provide a product TBZ compound having structure I. The method may be used to prepare either enantiomeric form of tetrabenazine; (+)-tetrabenazine or (-)-tetrabenazine. Alternatively the method may be adapted to provide a mixture enriched in one tetrabenazine enantiomer, a racemic mixture, or a diastereomeric mixture of tetrabenazine compounds. In addition, the present invention provides novel synthetic intermediate compositions which may be used to prepare either or both enantiomers of tetrabenazine, derivatives of tetrabenazine, and analogs of tetrabenazine.
Abstract:
An apparatus for producing and controlling an energetic pulse wave in a laminar flow having an at least one water input and a housing with a water channel flowing therethrough. At least one jetting element for jetting a laminar flow tube from a laminar flow passing through the water channel. With at least one energetic pulse wave generating element generating an energetic pulse in a controlled fashion that travels into the laminar flow and selectively interrupts the laminarity therein.
Abstract:
Current embodiments provide for authorization and payment of an online commercial transaction between a purchaser and a merchant including verification of an identity of the purchaser and verification of an ability of the purchaser to pay for the transaction, where the identity provider and the payment provider are often different network entities. Other embodiments also provide for protocols, computing systems, and other mechanisms that allow for identity and payment authentication using a mobile module, which establishes single or multilevel security over an untrusted network (e.g., the Internet). Still other embodiments also provide for a three-way secure communication between a merchant, consumer, and payment provider such that sensitive account information is opaque to the merchant, yet the merchant is sufficiently confident of the consumer's ability to pay for requested purchases. In yet another embodiment, electronic billing information is used for authorization, auditing, payment federation, and other purposes.